Abstract:Sir: Ziprasidone is an antipsychotic agent that is generally well tolerated.Allergic responses to ziprasidone have been reported, including immunoglobulin E (IgE)-related pedal edema, 1 lifethreatening hypersensitivity syndrome, 2 and angioedema. 3 We present a report of a patient who developed angioedema upon starting ziprasidone treatment. Case report.Mr A is a 30-year-old man who presented with psychotic symptoms characterized by persecutory delusions over a 6-week period.His diagnosis according to DSM-IV-TR was bipolar I disorder, most recent episode depressed, severe with psychotic features.He had had 2 previous episodes of mania with psychosis that were managed with short-term antipsychotic medication (olanzapine for the first episode and aripiprazole for the second) and maintenance mood stabilizers (lithium and sodium valproate for the second episode) without any adverse effects.Mr A's treating psychiatrist started him on ziprasidone therapy without any other concurrent medication.Prior to treatment with ziprasidone, Mr A had been free of all other prescription and nonprescription medication in the preceding 3 months.He commenced ziprasidone 20 mg twice daily on the first day and had a 40-mg tablet the next morning.Within 6 hours of taking the 40-mg dose, his tongue began to swell and he could not speak clearly.He experienced shortness of breath and was immediately transferred to the hospital by ambulance.Mr A had no past history of asthma, allergic rhinitis, urticaria, food allergies, eczematous dermatitis, or drug-related allergies.On examination, his tongue and lips were swollen, extending up to the jaw line.There was partial obstruction to the airway, and the patient found it difficult to breathe through the mouth.There was no swelling noted of the genitalia, palms, soles, or eyelids.He had tachycardia, mildly elevated blood pressure, and an oxygen saturation of 97%.There was no lymphadenopathy or urticarial lesions, and the findings from systemic examination were normal.The diagnostic impression was that Mr A's presentation possibly represented an anaphylactic reaction to ziprasidone.He was immediately treated with nebulized and intramuscular epinephrine, intravenous hydrocortisone, and promethazine.He responded to these interventions, and within 10 minutes, he was able to talk and breathe without distress.Within 4 hours, the swelling subsided completely, and he could tolerate oral fluids.Apart from a marginal increase in white cell count, the results of blood investigations were otherwise normal.Mr A was discharged from the medical unit after 48 hours and transferred to the psychiatric ward.The medical team advised the patient to continue oral prednisolone for 5 days.The adverse reaction scored 6 on Naranjo and colleagues' Adverse Drug Reaction (ADR) scale, 4 thus implicating ziprasidone as a probable cause for the event.While in the psychiatric unit, Mr A was commenced on amisulpride treatment after a 5-day medication-free period.There was no recurrence of angioedema with amisulpride.His psychotic symptoms improved within a week, and there were no further allergic reactions in the subsequent 3 months.

Aripiprazole-Associated Rhabdomyolysis in a 17-Year-Old Male

Rhabdomyolysis with Acute Renal Failure and Deep Vein Thrombosis Induced by Antipsychotic Drugs: A Case Report

Low-Dose Aripiprazole-Induced Nocturnal Enuresis in a 9-Year-Old Boy: A Case Report and the Possible Underlying Mechanism

Aripiprazole Augmentation in Managing Comorbid Obsessive-Compulsive Disorder and Bipolar Disorder: a Case with Suicidal Attempts.

Withdrawal Dyskinesia Associated With Aripiprazole in a Child: A Case Report

Rhabdomyolysis during adjunctive treatment with cariprazine in a clozapine-resistant schizophrenia patient

Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations

Aripiprazole induced reversible ptosis anda oromandibular dystonia

Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports

A safety evaluation of aripiprazole in the treatment of schizophrenia

Persistent hiccups due to aripiprazole: a case report and review of the literature

Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia

A Case Report of Recurrent Acute Laryngeal Dystonia With Different Novel Antipsychotics: Aripiprazole and Olanzapine

Aripiprazole-induced obsessive-compulsive symptoms

A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents

Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report

ARIPIPRAZOLE INDUCED COMPULSIVE EATING DISORDER: A CASE REPORT

Safety of Atypical Antipsychotics in a Child and Adolescent Inpatient Setting: A Naturalistic Study

In vitro cytogenotoxic evaluation of aripiprazole on human peripheral lymphocytes and computational molecular docking analysis

A descriptive study of aripiprazole, brexpiprazole, and cariprazine exposures in children ages 0 to 5 years reported to United States poison centers

Use of low-dose Aripiprazole to lower the antipsychotic medication - induced hyperprolactinemia.